In accordance with feedback from the Danish Medicines Agency we have performed
additional safety studies for SIS in a minipig inhalation model, resembling the
human respiratory tract. This study confirmed that mild changes to the
respiratory epithelium when exposed with higher concentrations of SIS have been
documented to be transient and fully reversible," says DVM Elin Jørgensen from
University of Copenhagen (in charge of animal studies). 

SoftOx Inhalation Solution (SIS) is an inhalation solution where the hypothesis
is that it should be able to treat all types of respiratory tract infections.
This could potentially be a paradigm shift in the treatment of all types of
respiratory infections.

"Safety-wise, these results are of outmost importance to SoftOx, as it provides
excellent grounds for pursuing safety testing in humans as planned in Q2 2021,"
says Medical Director at SoftOx, Glenn Gundersen. 

"This is excellent news and support our aim for SIS to become a well-tolerated
and effective treatment for COVID-19 patients and potentially other respiratory
infections," says Professor in Microbiology and Primary Investigator Thomas
Bjarnsholt*, University of Copenhagen and Rigshospitalet, Denmark.

*Professor Bjarnsholt is one of the inventors of the SoftOx technology, and he
is a member of the SoftOx Solutions AS advisory board. He owns options (20 000)
to acquire shares in the company, and he is being paid for his work for SoftOx
Solutions AS. 

Oslo, 16 December 2020

Contact:
Geir Almås, CEO of SoftOx Solutions AS
Email: geir.almaas@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS								            SoftOx Solutions AS (SoftOx, listed
on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based
in Oslo with the aim of helping to combat major threats to human health, namely
the emergence of antimicrobial resistance (AMR), biofilm infections in chronic
wounds and the spread of viruses. For more information on SoftOx, visit
www.soft-ox.com